Targeted Radioimmunotherapy Regimen Achieves Complete, Durable Response in Breast Cancer Model

tim.hodson

Tue, 11/04/2025 – 10:47

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses — including histologic cures — with minimal toxicities, paving the way for a saf…

Read the full article on itnonline.com